

RECEIVED  
CENTRAL FAX CENTER

003/010

FEB 01 2007

Appl. No. 09/847,102  
Amndt. dated February 1, 2007  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1642

PATENT**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously presented) A purified antibody that binds a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope in an amino terminal extracellular domain of the frizzled 5 receptor expressed on a malignant cell, wherein the amino terminal extracellular domain is SEQ ID NO:68, and wherein the antibody inhibits growth of the malignant cell that expresses the frizzled 5 receptor.
2. (Previously presented) The purified antibody of claim 1, wherein the extracellular domain comprises an amino terminal peptide fragment of the frizzled 5 receptor.
3. (Original) The purified antibody of claim 1 further comprising an antibody fragment having an antigen binding region that specifically binds to the epitope.
4. (Previously presented) The purified antibody of claim 1, wherein the antibody is capable of eliciting a cytotoxic response of the malignant cells expressing the frizzled 5 receptor.
5. (Previously presented) The purified antibody of claim 1, wherein the antibody interferes with the frizzled 5 receptor signaling pathway.
6. (Original) The purified antibody of claim 1 further comprising a detectable label.
7. (Original) The purified antibody of claim 1, wherein the antibody is a human antibody.

Appl. No. 09/847,102  
Amdt. dated February 1, 2007  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1642

PATENT

8. (Original) The purified antibody of claim 1, wherein the antibody is a monoclonal antibody.

9-15. (Cancelled)

16. (Previously presented) A pharmaceutical composition comprising a purified antibody that binds a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope in an amino terminal extracellular domain of the frizzled 5 receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier, and wherein the amino terminal extracellular domain is SEQ ID NO:68, and wherein the antibody inhibits growth of a malignant cell that expresses the frizzled 5 receptor.

17-27. (Cancelled)

28. (Previously presented) A purified antibody that binds a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope of the amino terminal extracellular domain of the frizzled 5 receptor expressed on the malignant cell, wherein the amino terminal extracellular domain is SEQ ID NO:68, and wherein the antibody is effective for immunotherapy of a malignant cell that overexpresses the frizzled 5 receptor.

29. (Previously presented) A pharmaceutical composition comprising the purified antibody of claim 28.